Neurocrine Biosciences, Updated View After The Failed Phase 2 Trial Of Valbenazine In Adult Tourette's Syndrome

NBIX, TEVA

We listened to the management's conference call after the phase 2 trial of Valbenazine in adults with Tourette's syndrome ((TS)) failed to achieve statistical significance of the primary end-point, Yale Global Tic severity scale. We do not consider this a major setback for the company.

Adults cons...

We listened to the management's conference call after the phase 2 trial of Valbenazine in adults with Tourette's syndrome ((TS)) failed to achieve statistical significance of the primary end-point, Yale Global Tic severity scale. We do not consider this a major setback for the company.

Adults cons...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics